Evidence map›Paper›PMID 31818267›Full record

ArticleBMC bioinformatics2019

Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network.

Hui Liu, Wenhao Zhang, Lixia Nie, Xiancheng Ding, Judong Luo, Ling Zou

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Frontiers in nutrition · 2022
    Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hui LiuLab of Information Management, Changzhou University, Jiangsu, China.
Wenhao ZhangLab of Information Management, Changzhou University, Jiangsu, China.
Lixia NieSchool of Information Science and Engineering, Changzhou University, Jiangsu, China.
Xiancheng DingInformation Center, Changzhou University, Jiangsu, 213164, China.
Judong LuoDepartment of Radiation Oncology, the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, China. judongluo@163.com.
Ling ZouSchool of Information Science and Engineering, Changzhou University, Jiangsu, China. zouling@cczu.edu.cn.ORCID http://orcid.org/0000-0001-5547-2871
Changzhou University · CNChangzhou No.2 People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough targeted drugs have contributed to impressive advances in the treatment of cancer patients, their clinical benefits on tumor therapies are greatly limited due to intrinsic and acquired resistance of cancer cells against such drugs. Drug combinations synergistically interfere with protein networks to inhibit the activity level of carcinogenic genes more effectively, and therefore play an increasingly important role in the treatment of complex disease.

resultsIn this paper, we combined the drug similarity network, protein similarity network and known drug-protein associations into a drug-protein heterogenous network. Next, we ran random walk with restart (RWR) on the heterogenous network using the combinatorial drug targets as the initial probability, and obtained the converged probability distribution as the feature vector of each drug combination. Taking these feature vectors as input, we trained a gradient tree boosting (GTB) classifier to predict new drug combinations. We conducted performance evaluation on the widely used drug combination data set derived from the DCDB database. The experimental results show that our method outperforms seven typical classifiers and traditional boosting algorithms.

conclusionsThe heterogeneous network-derived features introduced in our method are more informative and enriching compared to the primary ontology features, which results in better performance. In addition, from the perspective of network pharmacology, our method effectively exploits the topological attributes and interactions of drug targets in the overall biological network, which proves to be a systematic and reliable approach for drug discovery.

Indexed as

AlgorithmsDrug CombinationsDatabases, FactualGene OntologyHumansProbabilityProteinsROC CurveDrug CombinationsProteinsDrug combinationHeterogenous networkRandom walk

Identifiers

PMID31818267
PMCPMC6902475
OpenAlexW2994537342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.